By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the ...

SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...

GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its type in terms of total potential value.

AstraZeneca has returned to CSPC with a licensing deal for the Chinese company’s monthly injectables for obesity.

In an agreement that seemingly bodes well for the flow of pharmaceuticals between the two regions, the EU and India on Monday agreed to a sweeping free trade agreement that the European bloc has ...

Export-focused stocks jump on optimism around Europe exposure, as analysts suggest textiles, pharmaceuticals and chemicals ...

Sun Pharma is evaluating a potential $10 billion acquisition of Organon, a move that could become India's largest ...

Jan 30 (Reuters) - CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the ...